Innovative immunotherapy
XENOTHERA is addressing unmet medical needs with proprietary Glyco-Humanized Antibodies:
Therapeutic domains:
TEAM
Odile Duvaux
Chief Executive Officer
M.D., Ph. D., formerly main partner in a consultant firm specialized in strategy DMJ Consultants
More
Bernard Vanhove
Chief Operating Officer
Ph. D., immunilogist, formerly Research Director at CNRS and INSERM, co-founder and ex-COO of Effimune
More
Didier Coquoz
Clinical & Regulatory Affairs
PhD in clinical pharmacology, Chief Development and Regulatory Officer for biotech/small pharmas
More
Alexandre Lemoalle
Business Development
Former M&A VP for Sanofi, had many finance experiences in the pharmaceutical industry
More
Elsa Lheriteau
Project Manager
Ph. D. in Gene Therapy, Molecular Biology and Vectorology, University of Nantes, France
More
Carine Ciron
Research Engineer
Ph. D. in Gene Therapy, Molecular Biology and Vectorology, University of Nantes, France
More
Sophie Despons
Administration & Finance
External Contractor
Scientific advisor
Emanuele Cozzi
Chairman of the Scientific Advisory Board
MD, Professor of Immunology at the University of Padua, former chairman of the International Xenotransplantation Association
MoreExternal Contractor
Scientific advisor
Jean-Marie Bach
D.M.V., Ph.D., Professor at Oniris, Veterinary school of Nantes
More
External Contractor
Genetic Engineering
Cesare Galli
D.M.V., Ph.D., founder of the company Avantea (Cremona, Italy), worldwide renowned animal genetic engineer
MoreExternal Contractor
Development & Market Access
Marc Bouillet
M.D., former partner/CEO in several pharmaceutical companies and patient associations
MoreAn agile company with a fast-paced development
XENOTHERA is a clinical stage biotech at the top of innovation, which creates new therapeutic modes in numerous domains. Our patented technological platform is built on a double expertise of immunology and genetic engineering. It develops innovative approaches in immunotherapy by marketing Glyco-Humanized Polyclonal Antibodies (GH-pAb). Our antibodies are engineered to display high therapeutic properties. XENOTHERA’s platform ensures short-time development thanks to our mastery of the entire process, from animal genetics, choice of the immunogen, selection and purification of antibodies, and access to market authorization in accelerated timescale. Within less than 5 years, XENOTHERA has brought to clinic its first product LIS1, a novel induction treatment in Solid Organ Transplantation, addressing a $1Bn market. It has also established in vivo Proof-of-Concept in Immuno-Oncology and Multi-Drug Resistant infections.
Pipeline
Products in development
Latest News
[Press Release] Effectiveness of XAV-19 against SARS-CoV-2 variants
February 1, 2021. # Download our press release (english version) # Télécharger notre communiqué de presse (version française)
Read more[Newsletter] XENONEWS
March 2021 >> Official Xenothera newsletter /Lettre d’information officielle de Xenothera << # Download our newsletter (english version) # Télécharger notre newsletter (version française)
Read more[Newsletter] XENONEWS
February 2021 >> Official Xenothera newsletter /Lettre d’information officielle de Xenothera << # Download our newsletter (english version) # Télécharger notre newsletter (version française)
Read moreXenothera is built on a worldwide network of scientific & medical collaboration
Related scientific papers
XAV-19, a novel swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike, efficiently neutralizes B.1.1.7 British and B.1.351 South-African variants
B.Vanhove , S. Marot, B.Gaborit, G. Evanno , I.Malet, C.Ciron , P-J Royer , E. Lheriteau 1, S.Denié , F Raffi, O.Duvaux , A-G Marcelin , V. Calvez
April 5, 2021.
High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2
Vanhove, Duvaux et al, Xenothera.
July 25, 2020 LINKNext-generation Porcine Low Immunogenicity Anti-Lymphocyte Immunoglobulins shows selective depletion of T lymphocytes versus Treg and Breg
Rousse et al, ESOT 2019, Copenhagen, Denmark
LINKAnti-Neu5Gc responses in kidney allograft recipients after treatment with Rabbit Anti-Thymocyte Globulins.
Rousse et al, ESOT 2019, Copenhaguen, Denmark
LINKNext-generation Porcine Low Immunogenicity Anti-Lymphocyte immunoglobulins efficiently delay skin graft rejection in non-human primate
Ciron et al, ESOT 2019, Copenhagen, Denmark
LINKQuantitative and qualitative changes in anti-Neu5Gc antibody response following rabbit anti-thymocyte IgG induction in kidney allograft recipients
Rousse et al, Eur J Clin Invest. 2019. Apr;49 (4)
LINKAnti-Gal and anti-Neu5GC responses in non-immunosuppressed patients following treatment with Anti-Thymocyte Globulin
Salama et al, 2017
LINKNeu5Gc and α1-3 GAL Xenoantigen Knockout Does Not Affect Glycemia Homeostasis and Insulin Secretion in Pigs
Salama et al, 2017
LINKAnti-EBOV GP IgGs Lacking α1-3-Galactose and Neu5Gc Prolong Survival and Decrease Blood Viral Load in EBOV-Infected Guinea Pigs
Reynard et al, PLoS One. 2016
LINKRabbit antithymocyte globulin-induced serum sickness disease and human kidney graft survival
Couvrat-Desvergnes et al, J Clin Invest. 2015
LINKPotential deleterious role of anti-Neu5Gc antibodies in xenotransplantation.
Salama et al, Xenotransplantation. 2015
LINKLong-term IgG response to porcine Neu5Gc-antigens without transmission of PERV in burn patients treated with porcine skin xenografts
Scobie et al, J Immunol. 2013
LINKXenothera is a start-up in biotechnology, specialized in immunology, infectious diseases and oncology
Investors already trusted us since 2014 by funding the company for 8M€, completed with 13M€ non dilutive financing. We are raising an additional 45M€ in 2021 to develop our pipeline with venture capital. Our products will offer a substantial patient benefit and address unsolved major public health issues
To contact us, use the form or see our full contact below
Xenothera
1 rue Vauban – 44000 Nantes – France
careers@xenothera.com
Contact Presse : IZsoGood – Ingrid Zémor
ingrid@izsogood.co